non small cell lung cancer IIIb~?
Conditions
Interventions
B: Systemic chemotherapy and topical therapy (radioactive particle / RF)
C: Systemic chemotherapy and radiotherapy
D:Systemic chemotherapy plus topical therapy (radioactive particle / RF) +BAE
Sponsors
The First Affiliated Hospital of Zhangzhou University
Eligibility
Sex/Gender
All
Age
18 Years to 100 Years
Inclusion criteria
Inclusion criteria: 1. aged 18 years old (male or female) 2. histology and cytology confirmed 3. TNM tumor stage IIIb-IV, no operation indications for patients; 4. there is evidence of typical imaging 5. the expected survival time over 12 weeks In blood and liver function examination basically normal, the neutrophil cell >1.5*10^9/L, platelet 60*10^9/L, serum bilirubin efficiency 1.5 times the upper limit of normal value; without liver metastasis. The levels of ALT and AST is less than 2.5 times the upper limit of normal value; liver metastasis AST and alt is less than 5 times the upper limit of normal value; 7. the KPS score of >60; 8. enrolled in the clinical study of patients must sign the informed consent.
Exclusion criteria
Exclusion criteria: 1. the constitution of the patients is too weak, can not be tolerated or unwilling to accept operation; At the same time, 2 with other malignant tumors; 3. serious heart and lung dysfunction, can not tolerate the percutaneous lung puncture operation; 4. serious disease (diabetes and blood coagulation dysfunction) patients; 5. tumor puncture site bleeding, necrosis; 6. pregnant, lactating women and all single and nonparous young patients. 7. contrast agent, local anesthetic allergy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| disease control rate;overall survival; | — |
Contacts
Public ContactHan Xinwei
Outcome results
None listed